← Back to knowledge base

Hemp & CBD Market

Hemp & CBD Market

Legislative status as of 2026-04-19. The 2018 Farm Bill's dry-weight 0.3% delta-9 THC threshold remains operative. P.L. 119-37 (FY2026 Agriculture appropriations act, signed 2025-11-12) will, absent repeal or delay, narrow that definition to total THC ≤ 0.3% plus a 0.4 mg per-container cap and exclude all synthetic/converted cannabinoids — effective November 12, 2026. Two active delay/repeal bills (Rep. Nancy Mace repeal, Hemp Planting Predictability Act) and the separate 2026 Farm Bill (H.R. 7567, House Ag approved 2026-03-05) make the effective date itself a moving target. Verify current status before making compliance or catalog decisions.

Scope note. Regulatory + market reference. For pharmacology, mechanism of action, receptor binding, and epimer ratios on every compound discussed below, see cannabinoids.md — that file is the pharmacology canon and stays authoritative for the science. For state cannabis licensing frameworks (recreational / medical / CBD-only / decriminalized / illegal categories, seed-to-sale tracking systems, licensing structures), see legality.md — cannabis licensing and hemp regulation are separate regulatory tracks. This file covers the hemp track only: federal + state hemp rules, CBD product landscape, novel cannabinoid production/legal/safety profiles, and hemp vs cannabis market dynamics.

Summary

  • Hemp is a separate federal legal track from cannabis. The 2018 Farm Bill removed Cannabis sativa L. with delta-9 THC ≤ 0.3% (dry weight) from the Controlled Substances Act. Everything in this file flows from that one threshold. (HEMP-01)
  • The legal regime is in active transition. As of 2026-04-19, the 2018 Farm Bill rules are still operative. P.L. 119-37 (signed 2025-11-12) flips to total-THC + per-container cap + synthetic-exclusion on 2026-11-12 — 7 months out. Treat every legal-status claim as dated. (HEMP-01)
  • CBD is a regulated gray market. FDA has consistently held since 2019 that CBD cannot be a dietary supplement under the FD&C Act (DSHEA drug-first exclusion, Epidiolex precedent). 80+ warning letters since 2019. First formal enforcement framework submitted to White House OIRA mid-March 2026 — details not yet public. (HEMP-02)
  • Five hemp-derived cannabinoids drive current compliance anxiety. Delta-8 (CBD isomerization), hemp-derived Delta-9 (beverage/gummy wedge via dilution math), Delta-10 (isomerization), HHC (hydrogenation), THCP (extraction or synthesis). Every one becomes federally non-hemp on 2026-11-12 absent repeal. Production chemistry + safety + format + market here; pharmacology defers to cannabinoids.md. (HEMP-03)
  • Hemp-cannabinoid retail is roughly the size of state-licensed cannabis retail. Whitney Economics pegs total hemp-derived cannabinoid sales at $28.4B-$35.0B (2023 baseline, verify); legal US cannabis retail was ~$32B in 2024. Hemp is not a sideshow — it is a market-scale competitor for low-dose / beverage / canna-curious SKUs, not for heavy-user flower. (HEMP-04)
  • In scope: federal hemp statutory regime + state overlay highlights, CBD product categories and FDA stance, five-compound regulatory + market + production-safety profiles, market-dynamics and consumer-crossover analysis, Minnesota 2022 case study.
  • Out of scope: pharmacology and mechanism — see cannabinoids.md. State cannabis licensing and seed-to-sale tracking — see legality.md. Entourage-effect pharmacology — see entourage-effect.md. Cannabis 280E tax handling — see 280e.md.
  • Verify before action. Every state list, bill name, market figure, and FDA status claim is date-stamped or explicitly flagged. Re-check state status against the live trackers in §6 before advising or committing.

1. Farm Bill Landscape (HEMP-01)

1.1 The 2018 Farm Bill (Operative Law as of 2026-04-19)

Agriculture Improvement Act of 2018, P.L. 115-334, Section 10113. (Verified via congress.gov CRS R48637, 2026-04-19.)

  • Removed hemp from the federal Controlled Substances Act.
  • Defined hemp as Cannabis sativa L. and any part of the plant (seeds, derivatives, extracts, cannabinoids, isomers, acids, salts of isomers) with a delta-9 tetrahydrocannabinol concentration of not more than 0.3% on a dry-weight basis.
  • Created a federal licensing framework administered by USDA (state departments of agriculture operate under USDA-approved state plans).
  • FDA explicitly excluded cannabis-derived products (including CBD) from the dietary-supplement definition. (Verified via fda.gov press release 2023-01-26.)

The three-wedge structure. The 2018 Farm Bill definition contained three drafting choices the industry subsequently exploited to build the entire intoxicating-hemp market:

  1. "Delta-9" only (not "total THC"). This left delta-8, delta-10, HHC, and THCP outside the 0.3% threshold by statutory construction — the law measured one molecule, not intoxicating activity.
  2. "Dry weight" (not "per container"). A 100 g gummy with 10 mg of delta-9 THC is 0.01% by weight — well under 0.3%. Concentration-by-weight math let operators formulate intoxicating finished products that remained "hemp" under a literal reading.
  3. "THC" (not "all intoxicating cannabinoids"). The statute did not anticipate semi-synthetic cannabinoids produced by chemical conversion (CBD → delta-8, THC → HHC). Those were legal by default.

P.L. 119-37 is Congress closing all three wedges. Until it closes them (2026-11-12), the 2018 Farm Bill's literal reading is the operative federal rule.

1.2 P.L. 119-37 (Signed 2025-11-12, Effective 2026-11-12) — The Real Change

(Verified via Arnold & Porter 2025-12, DLA Piper 2025-11, Vicente LLP 2025-11, Perkins Coie 2025-11, Saul Ewing 2025-11, Frier Levitt 2026 — 2026-04-19.)

  • Not a Farm Bill reauthorization. P.L. 119-37 is the FY2026 Agriculture appropriations act, a continuing-resolution-style funding bill with hemp provisions attached as Division B. Writing that calls it the "2025 Farm Bill" is inaccurate — the actual 2026 Farm Bill is H.R. 7567, a separate bill at an earlier stage (see §1.3).
  • Signed November 12, 2025. Effective November 12, 2026 — a 365-day transition window from enactment. As of 2026-04-19, pre-P.L. 119-37 rules are still operative and ~7 months of transition remain.

Key provisions (what actually changes on 2026-11-12, absent repeal or delay):

  1. Total-THC standard. Hemp redefined as Cannabis sativa L. with total THC ≤ 0.3% dry weight, explicitly including THCA (which converts to delta-9 upon heating) and delta-8-THC in the calculation. Closes wedge #1.
  2. Per-container cap. Finished hemp-derived cannabinoid products are excluded from the "hemp" definition if they contain more than 0.4 mg total tetrahydrocannabinols per container. Destroys the dilution math that enabled the 10 mg THC gummy. Closes wedge #2.
  3. Synthetic / converted cannabinoid exclusion. Any cannabinoid produced by chemical synthesis or conversion (CBD → delta-8 isomerization, THC → HHC hydrogenation, THC-O-acetate, etc.) is excluded regardless of source plant. Eliminates the semi-synthetic category. Closes wedge #3.
  4. "Similar effects" clause. Bans any cannabinoid whose effects are "similar to THC" — a catch-all that captures novel compounds (HHC, THCP, HHC-P) even if not explicitly named. Reduces the need for compound-by-compound follow-on legislation.

Net effect. Delta-8, hemp-derived delta-9 gummies/beverages at typical potencies, delta-10, HHC, and THCP all become federally non-hemp on 2026-11-12 — and therefore federally controlled substances — absent a repeal or delay bill clearing Congress first.

1.3 Live Repeal / Delay Efforts (as of 2026-04-19)

(Verified via Cannabis Business Times 2026-04, Frier Levitt 2026. Verify current bill status before relying on any of the below.)

  • Rep. Nancy Mace (R-SC) repeal bill — Introduced 2025-11-20. Would repeal the P.L. 119-37 hemp provisions entirely before the 2026-11-12 effective date. (Verify current status, 2026-04-19.)
  • Hemp Planting Predictability Act (H.R. 7024) — Introduced 2026-01-13. Would replace the 365-day transition in P.L. 119-37 with a three-year transition, deferring the effective date to 2028-11-12. Industry-friendly framing; does not repeal substance. (Verify current status, 2026-04-19.)
  • 2026 Farm Bill — Farm, Food, and National Security Act of 2026 (H.R. 7567) — Approved 34-17 by the House Committee on Agriculture on 2026-03-05. Would independently adopt the total-THC standard in its own reauthorization text. Floor action pending. (Verify floor status and final text, 2026-04-19.)

State enforcement posture. The P.L. 119-37 federal effective date is 2026-11-12, but state enforcement can diverge in both directions. Some states may begin enforcing analogous restrictions earlier (a state can always be more restrictive than federal law). Others — particularly those with entrenched intoxicating-hemp markets — may challenge federal preemption, delay enforcement, or carve out state-licensed exceptions. Point clients to their state Attorney General and state hemp/cannabis regulator for current enforcement posture in their specific jurisdiction. Do not assume uniform national rollout on 2026-11-12.

1.4 FDA CBD Framework (Separate From Farm Bill)

(Verified via fda.gov 2023-01-26, cannabisregulations.ai 2026 OIRA coverage, Q3 2025 FDA warning-letter roundup — 2026-04-19.)

FDA regulation of CBD is a separate regulatory track from Farm Bill hemp legality. The 2018 Farm Bill descheduled hemp; it did not create a pathway for CBD as a dietary supplement or food additive. Four facts define the federal CBD landscape:

  1. FDA's consistent position since 2019: "Existing regulatory frameworks for foods and supplements are not appropriate for CBD." CBD cannot be a dietary supplement under the FD&C Act.
  2. The first formal CBD Compliance and Enforcement Policy was submitted by FDA to the White House Office of Information and Regulatory Affairs (OIRA) in mid-March 2026. First formal framework after ~8 years of enforcement discretion. Content not public as of 2026-04-19; OIRA review typically runs 60-90 days.
  3. 80+ FDA warning letters issued since 2019 to CBD companies for disease/health claims, unapproved-drug marketing, and misbranded supplement claims. FTC runs parallel enforcement on unsubstantiated efficacy claims under §5 of the FTC Act.
  4. FDA has NOT concluded CBD is GRAS (Generally Recognized as Safe) for any food or beverage use. Private GRAS self-affirmations exist but carry no FDA endorsement.

1.5 The 0.3% THC Threshold Explained

The 0.3% threshold is federal; it is also the single most consequential number in the hemp industry. Two refinements matter:

The dry-weight math. A 100 g gummy containing 10 mg of delta-9 THC is 0.01% delta-9 by weight — well below 0.3%. Under the 2018 Farm Bill's literal "delta-9 ≤ 0.3% dry weight" test, that gummy is "hemp." Under P.L. 119-37's per-container cap (0.4 mg total THC), it is not. The 0.4 mg cap is specifically designed to destroy this math. Every 10 mg / 5 mg hemp-derived delta-9 beverage and gummy on the market depends on the pre-P.L. 119-37 reading.

Total THC vs delta-9 THC. The 2018 Farm Bill measures delta-9 only. P.L. 119-37 switches to total THC — the sum of delta-9-THC, delta-8-THC, and THCA, the acidic precursor that converts to delta-9 upon heating (decarboxylation). This matters for flower: a hemp flower that reads 0.25% delta-9-THC and 1.5% THCA tests under the 2018 threshold but fails the P.L. 119-37 total-THC standard once the THCA converts. Most "hemp flower" sold as smokable today fails the total-THC test.

2. State Variation on Hemp Rules

State ban list entries verified against themarijuanaherald.com November 2025 state-by-state summary, MPP.org delta-8 tracker, and Calm by Wellness 2025 state guide. All entries as of 2026-04-19. Consult the MPP.org tracker in §6 for current status — this file is a snapshot; state rules change at sub-quarterly cadence.

The 0.3% threshold is federal. States may be more restrictive than federal law on their own residents. This section captures notable cases, not exhaustive 50-state coverage (per CONTEXT D-04 — focus on the bans that move market economics, not completeness).

2.1 States That Ban Delta-8 Outright (Notable, Not Exhaustive)

| State | Status | Notes | |-------|--------|-------| | Alaska | Banned | All intoxicating hemp products. (Verified themarijuanaherald.com Nov 2025, 2026-04-19.) | | Arizona | Banned | All intoxicating hemp products. (Verified 2026-04-19.) | | Colorado | Banned | Pre-dated P.L. 119-37 by ~3 years; one of the earliest intoxicating-hemp bans. (Verified 2026-04-19.) | | Delaware | Banned | All THC isomers Schedule I under state controlled-substance law. (Verified 2026-04-19.) | | Idaho | Banned | Maintains a 0.0% THC standard — stricter than federal 0.3%. (Verified 2026-04-19.) | | Iowa | Banned | Consumable delta-8 prohibited. (Verified 2026-04-19.) | | Montana | Banned | Consumable delta-8 prohibited. (Verified 2026-04-19.) | | New York | Banned | Among the earliest explicit bans (2021). (Verified 2026-04-19.) | | North Dakota | Banned | Consumable delta-8 prohibited. (Verified 2026-04-19.) | | Rhode Island | Banned | All intoxicating hemp products. (Verified 2026-04-19.) | | Utah | Banned | Consumable delta-8 prohibited. (Verified 2026-04-19.) | | Vermont | Banned | All synthetically-derived cannabinoids banned. (Verified 2026-04-19.) | | Washington | Banned | All intoxicating hemp products. (Verified 2026-04-19.) | | Oregon | Banned | Pre-dated P.L. 119-37; serving-size limits apply to what remains legal. (Verified 2026-04-19.) |

14+ states and counting — the list shifts. Treat this table as a dated snapshot and always cross-check the live tracker in §6.1 before advising on a specific state.

2.2 States With Regulated (Not Banned) Delta-8 Programs

(Verified Moonwlkr 2025 state guide and individual state statutes — 2026-04-19.)

  • California — Legal but licensed; strict potency caps; mandatory product testing. (Verify CA DCC guidance, 2026-04-19.)
  • Connecticut — Legal but licensed under state cannabis framework.
  • Michigan — Regulated under the existing state cannabis framework; intoxicating hemp products pushed into the licensed channel.
  • Louisiana — Regulated with serving-size limits.
  • Alabama — 2025 law: ≤ 10 mg THC per serving, ≤ 40 mg per package; vapes and smokables prohibited. First state to impose explicit per-serving / per-package caps through a dedicated intoxicating-hemp licensing statute rather than via the cannabis framework.
  • Texas — State-legal for most consumable hemp, BUT September 2025 banned all cannabinoid-containing vapes and e-cigarettes (including delta-8 vapes). Consumables (gummies, tinctures, beverages) remain legal. (Verify current status, 2026-04-19.)

2.3 Delta-10 / HHC / THCP State Coverage

Delta-10, HHC, and THCP rarely attract compound-specific state legislation. They are typically captured under broader "intoxicating hemp," "synthetic THC," "semi-synthetic cannabinoid," or catch-all "THC analog" language in state controlled-substance schedules.

  • Most delta-8 ban states also capture delta-10 and HHC under the same statutory language — check the ban's wording, not the compound name.
  • THCP is frequently captured under state-level analog-drug doctrine (mirroring the Federal Analogue Act, 21 U.S.C. § 813), regardless of explicit state legislation. A prosecutor's theory rather than a statute.
  • Several 2024-2025 wave states have explicitly named HHC in controlled-substance schedules before federal action.

2.4 Notable 2025-2026 State Changes

  • Texas (September 2025) — Vape/e-cigarette ban captured all cannabinoid-containing vapes. Reshaped the Texas intoxicating-hemp SKU mix overnight.
  • Alabama (2025) — First state to adopt explicit per-serving (≤ 10 mg) and per-package (≤ 40 mg) caps for intoxicating hemp through a dedicated licensing statute. Template that other states are watching.
  • Tennessee — Active hemp-derived THC market with an unusually permissive state-level posture. State legislature has debated restrictions multiple times without passing them. Watch 2026 session.
  • Minnesota (2022, ongoing) — The accidental mainstream-retail THC market; see §5.3 for the full case study.

3. CBD Product Landscape (HEMP-02)

3.1 Market Size & Formats

(Verified factmr.com CBD Market Analysis 2035, theinsightpartners.com CBD Gummies Report — 2026-04-19. Market-sizing figures are third-party estimates; verify for commitment decisions.)

  • Global CBD market 2025: ~$13.5B, projected ~$39B by 2035 (CAGR ~11.2%).
  • CBD gummies subsegment 2025: ~$5.89B, projected ~$33.19B by 2034 (CAGR ~20.5%) — fastest-growing format.
  • 2025 US format split (approximate): tinctures/oils ~36% (largest); gummies/edibles second, fastest-growing; topicals third; beverages emerging; pet products niche and growing; capsules/softgels mature niche; vapes declining under state restrictions.

3.2 Isolate vs Broad-Spectrum vs Full-Spectrum

All characterizations as of 2026-04-19. Formulation definitions are industry convention, not FDA-defined.

| Type | THC Content | Other Cannabinoids / Terpenes | Typical Use Case | |------|-------------|-------------------------------|------------------| | isolate | 0% (≥ 99% pure CBD) | None — pure crystalline CBD | Drug-tested workers, sensitive users, label-precision formulations | | broad-spectrum | 0% detectable | Minor cannabinoids (CBG, CBN, CBC) + terpenes, THC chromatographically removed | Users wanting entourage-style synergy without THC exposure | | full-spectrum | ≤ 0.3% delta-9 (legal hemp cap) | All hemp-plant cannabinoids + terpenes | Users accepting trace THC for maximum entourage synergy |

The three categories exist because the entourage effect — the hypothesis that minor cannabinoids and terpenes enhance CBD's effects — is a real part of the consumer value proposition even though clinical evidence is mixed. For formulation/market angle, this file covers how the category is sold. For the entourage-effect pharmacology itself, see entourage-effect.md.

3.3 FDA Regulatory Gray Areas

CBD regulation is the canonical case study in FDA enforcement discretion. Seven gray areas matter operationally:

  1. Dietary-supplement exclusion. FDA has consistently held since 2019 that CBD cannot be a dietary supplement under the FD&C Act. CBD products marketed as "dietary supplements" are federally misbranded. Enforcement has been discretionary — hence the gray market — but discretion is not legality.
  2. DSHEA interaction — Epidiolex precedent. FD&C Act § 201(ff)(3)(B) excludes from the dietary-supplement definition any substance that was authorized for investigation as a new drug and substantially studied as a drug before being marketed as a food or supplement. CBD was studied as Epidiolex (approved June 2018 for pediatric Dravet and Lennox-Gastaut syndromes) before the 2018 Farm Bill descheduled hemp. This is a statutory bar, not a discretionary preference — Congress would have to amend DSHEA to change it.
  3. CBD in food and beverages. Federal posture: "not permitted" under § 201(ff)(3)(B). State posture varies: California, Colorado, Oregon, Washington, Maine explicitly permit; New York prohibited until 2023; many states silent. National brands typically pick a subset for food/beverage SKUs and topicals-only for the rest.
  4. Cosmetics. Lowest-risk CBD category. No FDA warning letters absent health claims. Safe default SKU category for new CBD entrants.
  5. Health-claims enforcement (FDA + FTC). 80+ FDA warning letters since 2019 for disease claims (cancer, Alzheimer's, COVID, opioid-withdrawal). FTC runs parallel enforcement under FTC Act §5 against unsubstantiated efficacy claims.
  6. Serving-size + labeling standards. No federal standard; state variation wide.
  7. Coming change (mid-March 2026 OIRA framework). FDA submitted the first formal CBD Compliance and Enforcement Policy to OIRA in mid-March 2026. Details not yet public; expected to codify what has been discretionary.

3.4 DSHEA Interaction — Why CBD Can't Be a Dietary Supplement

The DSHEA exclusion (FD&C § 201(ff)(3)(B)) is the strongest statutory lever behind FDA's CBD posture. It excludes from "dietary ingredient" status any substance that was (a) authorized for investigation as a new drug with publicly disclosed substantial clinical investigations, and (b) not marketed as a supplement or food before that authorization.

CBD meets both prongs: authorized as Epidiolex pre-2018, and not marketed as a supplement before that authorization in any form FDA recognized. Congress can create an exemption by amending DSHEA or passing a CBD-specific pathway. Absent such action, FDA's position has solid statutory footing — not just discretion.

3.5 CBD in Food, Beverages, Cosmetics — State Variation

  • Food and beverages. Federal: not permitted (supplement-exclusion logic extends). State: California, Colorado, Oregon, Washington, Maine explicitly permit under state labeling and serving-size rules. New York prohibited pre-2023; now permits under state cannabis-management-adjacent rules. Texas and Florida: state guidance is permissive but not statutory; federal posture technically governs. Most other states silent.
  • Cosmetics and topicals. Low-risk. Federal: no warning letters absent health claims. State: most states permit without specific rules.
  • Beverages and shelf-stability. Hemp-CBD beverages share emulsification + stability challenges with hemp-delta-9 beverages — formulation cost, not a regulatory issue.

3.6 Health Claims Enforcement (FDA + FTC)

Two-agency enforcement is the practical CBD compliance risk:

  • FDA. Warning letters (80+ since 2019) issued when products claim specific diseases or symptoms — cancer, Alzheimer's, opioid withdrawal, COVID, PTSD, anxiety, chronic pain. Letters cite misbranding (§ 502), unapproved-drug status (§ 505), and dietary-supplement exclusion (§ 201(ff)).
  • FTC. Enforcement under FTC Act § 5 against unsubstantiated efficacy claims. "Competent and reliable scientific evidence" standard — typically well-controlled human trials. FTC and FDA can act against the same product under overlapping violations.

Practical rule. Wellness-framed language (general wellness, stress, sleep, relaxation) carries less exposure than disease- or symptom-specific claims. "May support stress relief" is lower-risk than "treats anxiety." Claim-substantiation convention, not a green light — any claim can be challenged.

4. Hemp-Derived Cannabinoids (HEMP-03)

Cross-reference boundary. Pharmacology, mechanism of action, epimer ratios, and receptor binding for every compound in this section live in cannabinoids.md. This file covers only production chemistry (isomerization / hydrogenation / extraction), regulatory status (federal + state + trajectory), safety from an epidemiology / FDA-reporting angle, product formats, and market size/context. For the science, defer to cannabinoids.md. Every compound subsection below opens with an explicit *see cannabinoids.md* pointer.

4.1 Delta-8-THC

For pharmacology, mechanism, and receptor binding on Delta-8-THC, see cannabinoids.md §Delta-8-THC.

Production mechanism. Acid-catalyzed isomerization of hemp-derived CBD. Typical reagents: Lewis acids (p-toluenesulfonic acid, BF₃ diethyl etherate) in a non-polar solvent system (toluene, heptane). The CBD molecule rearranges under acid catalysis to delta-8-THC. Reaction yield is modest (~50-60%) and commonly produces byproducts including delta-9-THC, delta-10-THC, iso-THC, olivetol, and unknown isomers that standard cannabis analytical panels do not characterize. The production chemistry is the source of the safety concern: the commercial delta-8 supply chain ships uncharacterized cannabinoid byproducts and residual solvents that no regulatory panel screens for. Few labs test beyond potency.

Federal legal status (as of 2026-04-19). Delta-8 is still operating under the 2018 Farm Bill's dry-weight 0.3% delta-9 threshold. Hemp-derived delta-8 is federally legal when produced from compliant hemp and the final product contains < 0.3% delta-9. Will be banned November 12, 2026 under P.L. 119-37's synthetic-cannabinoid exclusion (acid-catalyzed isomerization is conversion/synthesis by statute). AK Futures LLC v. Boyd Street Distro, LLC (4th Cir. 2022) ruled delta-8 federally legal under the 2018 Farm Bill; DEA guidance had contradicted that. P.L. 119-37 resolves the split by statute.

State status. Banned outright in 14+ states (see §2.1). Regulated in ~6 states (see §2.2). Permitted under hemp rules in remaining states as of 2026-04-19 — many are expected to harmonize with P.L. 119-37 at or before the federal effective date.

Safety concerns. (Verified via FDA Consumer Update "5 Things to Know about Delta-8-THC" and PMC 2024 poison-control study, 2026-04-19.)

  • 2,362 poison control exposures reported January 2021 through February 2022.
  • 55% required medical intervention or hospital admission.
  • 41% pediatric (< 18), with 82% of unintentional exposures involving children — driven directly by gummy, candy, and chocolate formats mimicking mainstream snack brands.
  • Reported symptoms: hallucinations, vomiting, tremor, anxiety, dizziness, confusion, loss of consciousness.
  • 11% of US 12th graders reported delta-8 use (2024 JAMA adolescent-use study).
  • Byproduct and residual-solvent contamination is systemic. The supply-chain testing gap is the core safety issue, not the molecule.

Product formats. Gummies (primary), vape cartridges, tinctures, flower sprayed with delta-8 distillate ("moon rocks"), beverages, chocolates, disposable vapes. Mainstream retail: grocery, liquor, convenience, DTC online — not the dispensary channel.

Market size. Peaked at ~$2B annual sales by 2023; compressing under state bans since. Post-P.L. 119-37 transition, the federally-legal delta-8 market is expected to collapse to illicit-market levels.

4.2 Delta-9-THC (Hemp-Derived) — The Beverage/Gummy Wedge

For pharmacology, see cannabinoids.md §Delta-9-THC — hemp-derived delta-9-THC is the same molecule as cannabis-derived delta-9-THC. The "hemp" framing is legal, not chemical.

Production mechanism — math, not chemistry. Under the 2018 Farm Bill, "hemp" is defined by dry-weight 0.3% delta-9 THC. A 100 g gummy-pack containing 10 mg total delta-9 THC is 0.01% by weight — well under 0.3%. A federally-legal "hemp" gummy under a literal reading of the 2018 Farm Bill. That is the entire wedge.

How the mechanics work:

  1. Farmer grows hemp (delta-9 ≤ 0.3% dry weight at harvest, per USDA sampling).
  2. Processor extracts total CBD and minor cannabinoids including natural trace delta-9.
  3. Processor either (a) separates natural delta-9 via preparative chromatography, or (b) isomerizes CBD to delta-9-THC (same chemistry family as delta-8, different reaction conditions).
  4. Final product (beverage, gummy, tincture) is formulated to contain 2-10 mg delta-9 per serving, in a carrier large enough that the delta-9 percentage stays under 0.3% by total product weight.
  5. Sold through mainstream retail — grocery, liquor, gas station, bars, DTC online. Not through dispensaries (dispensary licensing typically does not cover hemp SKUs).

Federal legal status (as of 2026-04-19). Still legal under the 2018 Farm Bill. A 10 mg hemp-derived delta-9 gummy or beverage is federally legal under literal reading. Will be banned November 12, 2026 under P.L. 119-37's 0.4 mg-per-container total-THC cap — which destroys the dilution math.

State status. Highly variable. Minnesota explicitly permits (2022 THC law, 5 mg/serving, 50 mg/package). Texas permits consumables but banned vapes (2025-09). Tennessee has an active market. Many states silent or ambiguous. See §5.3 for the Minnesota case study.

Safety concerns. Pharmacologically identical to cannabis-derived delta-9-THC. The safety risk is not the molecule — it is the unregulated supply chain (FDA reports labeled-vs-actual potency discrepancies up to 4x in hemp gummy products tested 2022-2024), labeling variability, and lighter age-of-purchaser enforcement at non-dispensary retail (gas stations, liquor stores, convenience). FDA adverse-event reporting does not cleanly separate hemp-delta-9 from delta-8 cases.

Product formats. Primarily beverages (CANN, High Hopes, Cycling Frog, Hi-Fi Hops are well-known brand names), gummies, some tinctures. Mainstream-retail positioned.

Market size. Hemp-derived THC beverages ~$600M in 2025. (Verified via Whitney Economics + Cannabis Business Times, 2026-04-19; Whitney 2024 beverage report pegged THC beverages at $1.1B including licensed-cannabis beverages.) Bull-case projections suggest $10-15B potential. Minnesota alone drove > $200M in first-wave sales after its 2022 law — proof that mainstream-retail distribution works at scale.

4.3 Delta-10-THC

For pharmacology and receptor binding on Delta-10-THC, see cannabinoids.md §Delta-10-THC.

Production mechanism. Chemical conversion from CBD, similar to delta-8 isomerization but with different reaction conditions (specific catalysts, higher temperature). Natural occurrence is ultra-trace. Discovered commercially in 2020 when a California lab found unusual cannabinoids in fire-retardant-contaminated hemp extract.

Federal legal status. Same trajectory as delta-8. Legal under the 2018 Farm Bill as of 2026-04-19; banned November 12, 2026 under P.L. 119-37.

State status. Most states that banned delta-8 also banned delta-10; few passed delta-10-specific legislation. Generally captured under "synthetic THC" or "intoxicating hemp" language. Estimate ~12 states banned as of 2026-04-19.

Potency. Typically described as 30-50% of delta-9-THC subjective potency (milder than delta-8). Marketed as "energizing" or "sativa-like" — based on consumer-report convention, not clinical pharmacology.

Safety concerns. Same isomerization-byproduct concerns as delta-8 — unknown cannabinoid isomers, residual solvents, no standardized testing panel. Less clinical and adverse-event data exists because the market is smaller; absence of documented harm is not evidence of safety given small-sample epidemiology.

Product formats. Vape cartridges, gummies; often blended with delta-8 in "D8/D10 blend" products that muddy per-compound dosing.

Market size. Substantially smaller than delta-8. No reliable standalone figure. Usually subsumed under the broader "intoxicating hemp" category in industry reporting.

4.4 HHC (Hexahydrocannabinol)

For pharmacology including epimer ratios (9R vs 9S) and receptor binding on HHC, see cannabinoids.md §HHC.

Production mechanism. Hydrogenation of THC or CBD — adding hydrogen atoms across the THC/CBD double bond. Chemistry analogous to how vegetable oil is hydrogenated into margarine. HHC occurs naturally in trace amounts in cannabis seeds and pollen (Roger Adams first synthesized it in 1944); commercial HHC is ~100% synthesized rather than extracted. Commercial HHC ships as a mixture of two epimers — the ratio is the key quality differentiator, and few labs report it on Certificates of Analysis. The hidden quality signal in HHC procurement.

Federal legal status. Same trajectory as delta-8/10. Legal under the 2018 Farm Bill as of 2026-04-19. Banned November 12, 2026 under P.L. 119-37 via both the synthetic-cannabinoid exclusion (hydrogenation is chemical conversion) and the "similar effects" clause.

State status. Banned in most states that have addressed intoxicating hemp; estimate ~12 states. Several states named HHC explicitly in controlled-substance schedules before federal action.

Potency. Typically described as 70-80% of delta-9-THC subjective potency — closer to delta-9 than delta-8 is.

Safety concerns. Limited formal research. Two practical concerns:

  • "Does not trigger standard drug tests" is largely unverified and potentially misleading. HHC metabolites may cross-react with immunoassay THC drug screens; no published rigorous cross-reactivity studies. Workplace-testing advising should not rely on HHC as a "legal" alternative.
  • Stability advantage is real but pharmacologically irrelevant. The hydrogenated structure resists heat, UV, and oxidation better than THC — genuine shelf-life benefit. Does not change effects.

Product formats. Vape cartridges, gummies, distillates. Often positioned as "long-shelf-life legal THC alternative." Drug-test positioning is a procurement red flag.

Market size. Peaked as a delta-8 substitute in 2023-2024 after state delta-8 bans accelerated. Smaller market than delta-8; no reliable standalone figure.

4.5 THCP (Tetrahydrocannabiphorol)

For pharmacology including the side-chain-length principle and CB1 binding-affinity details, see cannabinoids.md §THCP.

Production mechanism. Naturally biosynthesized in the cannabis plant at extremely low concentrations — discovered in 2019 in the Italian medical-cannabis FM2 cultivar. Differs from THC structurally by an extended 7-carbon alkyl (heptyl) side chain versus THC's 5-carbon (pentyl). Commercial THCP is hemp-extracted or synthesized; natural concentrations are too low for commercial extraction from typical hemp cultivars.

Federal legal status. The most legally ambiguous compound in the group. Not explicitly scheduled. Likely captured by the Federal Analogue Act (21 U.S.C. § 813) as a THC analog — a prosecutor's theory rather than a settled judicial finding. Banned November 12, 2026 under P.L. 119-37's "similar effects" clause, regardless of source plant.

State status. Increasingly restricted; often captured under catch-all "synthetic THC" or "intoxicating hemp" language rather than THCP-specific legislation. State-level analog-drug doctrines extend the Analogue-Act framing into state courts.

Potency — the 33x caveat. Receptor assays show THCP has ~33x the CB1 binding affinity of delta-9-THC. This is binding affinity, not subjective potency. The relationship between binding affinity and felt potency is non-linear — pharmacokinetics (absorption, distribution, metabolism, elimination) substantially moderate the in vivo effect. Consumer reports describe THCP edibles as "much stronger per mg than THC," but rigorous quantified human dose-response data does not exist. Reporting "THCP is 33x stronger than THC" as a subjective-potency claim is a common industry error.

Safety concerns. THCP is the highest-risk novel cannabinoid for accidental over-consumption. Consumer reports document unexpectedly intense experiences at doses that would be mild for delta-9-THC. Products are frequently marketed on potency as a selling feature without clear dose-equivalence guidance (a "10 mg THCP gummy" may produce effects equivalent to 100-200 mg delta-9 THC — unverified but consistent with aggregate consumer reports). Animal studies show hypomotility (reduced voluntary movement) at high doses. First-time-user risk is the practical retail concern.

Product formats. Vape cartridges, edibles marketed on "extreme potency." Low-volume premium positioning.

Market size. Small relative to delta-8 and HHC. No reliable standalone figure.

4.6 Summary Comparison Table

All legal-status cells as of 2026-04-19. State-ban counts are snapshot; verify against MPP.org tracker before commitment.

| Compound | Natural | Production | Potency vs Δ9 | Federal (2026-04) | Federal (2026-11) | State Bans | |----------|---------|------------|---------------|-------------------|-------------------|------------| | Delta-8 | Trace | CBD isomerization | 50-75% | Legal (hemp) | Banned | 14+ states | | Delta-9 (hemp-derived) | Yes | Extraction or isomerization | 100% (same molecule) | Legal if < 0.3% DW | Banned (0.4 mg cap) | Highly variable | | Delta-10 | Ultra-trace | CBD chemical conversion | 30-50% | Legal (hemp) | Banned | ~12 states | | HHC | Trace (seeds/pollen) | Hydrogenation of THC/CBD | 70-80% | Legal (hemp) | Banned | ~12 states | | THCP | Yes (< 0.1%) | Hemp extraction or synthesis | 33x binding affinity, unclear subjective | Analogue Act risk | Banned (similar-effects clause) | Variable |

5. Hemp vs Cannabis Market Dynamics (HEMP-04)

5.1 Market Size Context

(Verified via Whitney Economics 2023 U.S. National Cannabinoid Report; figures are 2023 baseline per RESEARCH Assumption A1 — verify latest Whitney update before using in client-facing materials. 2026-04-19.)

  • Total hemp-derived cannabinoid sales (intoxicating + non-intoxicating): $28.4B-$35.0B annually. (2023 Whitney baseline.)
  • Economic activity at retail / manufacturing / wholesale: $19.1B-$22.4B.
  • Annual industry wages: $1.6B+.

For context, legal US cannabis retail was ~$32B in 2024 (Headset / BDSA). Hemp-derived cannabinoid retail is approximately the same size as the state-regulated cannabis market. Operators who assume hemp is a sideshow are mis-sizing competitive dynamics by an order of magnitude.

5.2 Why Delta-8 and Hemp-Derived THC Grew — Regulatory Arbitrage Mechanics

Four forces explain the 2019-2025 intoxicating-hemp market explosion. Calling this regulatory arbitrage is accurate — the market exists because of a price and access gap between federally-controlled state-licensed cannabis and federally-descheduled hemp.

  1. Price gap. State-licensed cannabis carries 280E tax exposure (effective 45-70% total tax burden; see 280e.md), state cannabis excise + sales tax, and compliance-driven COGS. Hemp sidesteps all of it. A 10-pack of hemp-derived delta-9 5 mg gummies retails for $15-25; a state-licensed cannabis equivalent retails for $30-60. Hemp is consistently ~50% cheaper at the shelf on like-for-like dose.
  2. Accessibility. Cannabis dispensaries are scarce — limited licensing in most states, mostly single-store or small-chain. Hemp products sell through grocery, liquor, convenience, bars, DTC online — ~1/10th the consumer friction. A consumer can acquire a hemp THC beverage while buying groceries; a cannabis beverage requires a separate trip to a dispensary.
  3. Regulatory gap. The 2018 Farm Bill's three wedge points (§1.1) combined with FDA's enforcement discretion created a ~7-year window where the intoxicating-hemp industry grew materially unregulated at the federal level. Supply preceded state response; state response preceded federal response.
  4. Consumer crossover. Whitney Economics and Brightfield survey data consistently show ~50-60% of hemp-derived THC beverage buyers are current or former cannabis consumers choosing hemp for price or convenience. The remaining ~40-50% are cannabis-curious consumers who would not enter a dispensary. (Full demographic picture in §5.5.)

5.3 The Minnesota Case Study

(Verified via Minnesota 2022 hemp-THC law, Minnesota Office of Cannabis Management coverage, Cannabis Business Times reporting — 2026-04-19.)

Minnesota's 2022 hemp-THC law is the cleanest proof point for the mainstream-retail intoxicating-hemp thesis:

  • 2022 law. Permitted hemp-derived THC products sold through any retailer to adults 21+. 5 mg THC per serving, 50 mg per package. No dispensary license required.
  • First-wave sales: > $200M through non-dispensary channels — grocery, liquor, bars, restaurants. Mainstream retail absorbed the demand with minimal friction.
  • Drove subsequent 2023 legislation establishing full adult-use cannabis, effective 2025. The hemp-THC market served as consumer on-ramp and political proof-of-concept for full legalization.
  • Proof point for operators: mainstream retail distribution (liquor / grocery / bars) can dwarf dispensary-channel economics for low-dose THC products. The consumer base buying hemp-THC beverages is largely not the dispensary consumer base — different demographics, different occasions, different dose preferences.

Tennessee has shown analogous dynamics on a smaller scale — active hemp-derived THC market with mainstream-retail distribution — though without comparable state data transparency.

5.4 Cannibalization Evidence

(Partial verification: Cannabis Business Times reporting, Beverage Industry coverage, Whitney Economics industry-sentiment survey. Directional, not definitive. 2026-04-19.)

  • State-licensed cannabis retailers in hemp-adjacent states (TN, TX, FL, MN) report flat-to-declining beverage and low-dose edible SKU velocity attributed to hemp-derived substitutes available in non-dispensary retail.
  • Flower and high-dose product sales largely unaffected. Hemp competes in the beverage / low-dose / occasional-use segment, not in the heavy-user dispensary base. Pre-rolls, concentrates, high-dose edibles, and flower carts show stable velocity in the same markets.
  • 80% of cannabis businesses support regulating intoxicating hemp products (Whitney Economics / cannabisindustrydata.com 2025 industry survey). The licensed industry views hemp as an existential competitor in specific SKU categories — not a peripheral concern.

The cannibalization pattern is SKU-segmented, not across-the-board. Licensed operators responding by matching price on low-dose beverages and expanding low-dose edible assortment capture the canna-curious adjacency; those who ignore hemp cede the low-dose shelf entirely.

5.5 Consumer Crossover Data

(Medium confidence — survey data cited secondhand from industry press; Brightfield + Whitney Economics + Headset are underlying sources. Exact figures vary by study and vintage. 2026-04-19.)

  • Demographic tilt. Hemp-THC-beverage buyers skew older (35-55), higher-income, "wellness"-positioned, and more female than typical dispensary flower buyers. Segmentation looks closer to craft-beer or functional-beverage demographics than to cannabis-flower demographics.
  • Purchase motivations (approximate share citing each as primary reason): price (40-50%), convenience / proximity (25-30%), avoidance of cannabis stigma / non-dispensary preference (15-20%), curiosity (5-10%).
  • Dose preference. Overwhelmingly low-dose: 2-10 mg per serving, session-use, not daily. Use occasion looks more like wine or craft beer than like cannabis flower.
  • Crossover rate. ~50-60% of hemp-THC beverage buyers are current or former cannabis consumers. The other ~40-50% are cannabis-curious consumers who would not otherwise enter a dispensary.

Implication for dispensary operators. Hemp is not eating the core flower / concentrate / high-dose edible business. It is eating (or capturing) the low-dose / canna-curious / wellness-beverage adjacency. The segment is real and growing.

5.6 Price Delta (Licensed vs Hemp-Derived) — Illustrative

Illustrative. Actual prices vary by state tax regime, brand tier, and promotional cadence. 2026-04-19.

| Product | State-Licensed Cannabis | Hemp-Derived Equivalent | Delta | |---------|-------------------------|-------------------------|-------| | 5 mg THC beverage (12 oz) | $6-10 | $3-5 | ~2x | | 10-pack of 5 mg THC gummies | $25-40 | $12-20 | ~2x | | 100 mg disposable vape | $40-60 | $20-35 | 1.5-2x |

The ~2x price differential is stable across product categories and is the headline competitive pressure on licensed low-dose SKUs. State tax regime is the dominant variable — a high-excise state like California widens the gap; a low-excise state like Michigan narrows it.

5.7 Operator Response Options

Dispensary operators facing hemp competition have four documented response patterns:

  1. Match price on low-dose beverages and edibles. Accept margin compression to defend the low-dose shelf. Works in states where excise math allows; breaks in high-tax states.
  2. Expand low-dose SKU adjacency. Broaden the 2-5 mg beverage and edible assortment to capture canna-curious consumers who would otherwise buy hemp. Use the dispensary environment's product-knowledge advantage — trained staff can educate, mainstream retail cannot.
  3. Partner with hemp beverage brands. Some MSOs have either acquired or licensed hemp-derived beverage brands and operate them as separate non-dispensary lines. Revenue diversification; does not defend the dispensary channel directly.
  4. Advocate for state-level intoxicating-hemp regulation. The 80% industry-support figure in §5.4 is the political basis for state-level action. State legislatures in TN, TX, FL, and others have considered intoxicating-hemp regulatory frameworks in 2025-2026 in response to licensed-industry advocacy.

Options 1 and 2 are operational; options 3 and 4 are strategic. A serious hemp response typically combines operational (1 + 2) with at least one strategic move.

5.8 Implications for Catalog Migrations

Catalog migrations originating from hemp-focused POS systems (or hybrid cannabis/hemp operators) frequently contain delta-8, delta-10, HHC, and hemp-derived delta-9 SKUs that require compliance flagging before they flow into a state-licensed cannabis catalog. Typical issues: hemp-derived intoxicating SKUs that cannot be sold through the licensed cannabis channel in the destination state (category mismatch); hemp SKUs with serving-size / per-container potencies that pass mainstream-retail rules but fail state cannabis dosing caps; HHC, THCP, or delta-10 SKUs where the destination state's controlled-substance schedule captures the compound under analog / similar-effects language.

For per-compound SKU-handling detail and the pharmacology-level reasoning behind the category boundaries, see cannabinoids.md §Practical relevance. Catalog migrations involving hemp SKUs should route through a compliance review step rather than bulk-mapping into the licensed cannabis catalog.

6. Key Disclaimers & Sources

6.1 Verify Current Status — Suggested Live Trackers

This file is a dated snapshot as of 2026-04-19. Hemp and CBD regulation changes faster than quarterly review cycles. For current state status before any compliance, sourcing, or catalog decision, consult:

Consult these for current state status. Do not rely on this file as a live compliance feed.

6.2 Sources (Tiered by Confidence)

Primary (HIGH confidence — statutory or agency-direct):

Secondary (MEDIUM confidence — multi-source verified legal advisories):

Tertiary (LOW confidence — single-source, industry publications):

Sources as of 2026-04-19. Each link's freshness should be re-verified on next quarterly review. Regulatory advisories (Secondary tier) update most reliably; vendor sources (Tertiary) update inconsistently.